The Inno4Vac project aims to further develop vaccine technology on all fronts: from improving production facilities, to new in vivo and in vitro models for vaccine testing, to prediction of good vaccine candidates.
Traditional animal models such as mice, rats, and rabbits are commonly used in antibody discovery for therapeutic, diagnostic, and research purposes. They are cost-effective, versatile, and widely accepted in research settings.
Being ISO 27001:2013 certified means that ENPICOM has a world-class security system in place. We are committed to pursuing excellence in our business operations, technology, and customer experience.
Discover how you can use structural modeling to identify antibody liabilities and developability profiles for thousands of sequences at once.
The new IGX-Track App expands the capabilities of the IGX Platform by adding seamless analysis of antibody panning campaigns.
Genovac, a leading CRO/CMO that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, will utilize ENPICOM’s IGX Platform for antibody discovery workflows.
Now powered by AWS, ENPICOM can further accelerate scientific breakthroughs and enable scientists to harness the latest scientific advances.
Discover how you can perform advanced phylogenetic analysis, understand B cell lineages and the affinity maturation process to expand your antibody candidate pool.
ENPICOM has secured funding from BOP Capital to support the growth of their unique SaaS platform for therapeutic antibody discovery.
Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 that aims to foster health innovation by incorporating scientific and technological breakthrough from the academic and biotech sectors into industry.
ENPICOM